# Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

> **NCT06154902** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 350 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Idecabtagene vicleucel
- **OTHER:** Not treated

## Key facts

- **NCT ID:** NCT06154902
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-29
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06154902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06154902, "Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06154902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*